

AS AT OCTOBER 31, 2019

## FUND OVERVIEW

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

## FUND DETAILS

Inception date	December 2001
Total net assets (\$CAD) As at 2019-10-31	\$180.1 million
NAVPS	\$31.2546
MER (%)	Information not available
Management fee (%)	-
Asset class	Industry-Specific
Currency	CAD
Minimum investment	Negotiable
Distribution frequency	Quarterly
Last distribution	\$0.6446

## Risk rating<sup>3</sup>



## FUND CODES

I	886
A	ISC 201 DSC 701 LL 1701
E	16005
EF	15005
F	224
O	18005
P	90024
Y	4924
Z	ISC 2924 DSC 2925 LL 2928

## DISTRIBUTION HISTORY<sup>4</sup>


Payable date	Total	Payable date	Total
2019-09-27	0.4327	2018-06-22	0.0982
2019-06-21	0.4049	2018-03-23	0.6771
2019-03-22	0.6446	2017-03-31	0.2545
2018-12-14	0.1003	2016-03-24	1.5846
2018-09-14	0.0987	2015-03-27	1.9453

## PERFORMANCE<sup>1</sup>

Growth of \$10,000 (since inception date)



## Calendar year performance



## Average annual compound returns

YTD	1 Mo	3 Mo	6 Mo	1 Y	3 Y	5 Y	10 Y	Inception*
-%	4.4%	-0.9%	-7.2%	-6.9%	3.7%	2.8%	13.8%	8.0%

\*Since inception date

## PORTFOLIO ALLOCATIONS<sup>2</sup>

Asset allocation	(%)	Sector allocation	(%)
US Equity	59.40%	Healthcare	83.72%
International Equity	36.01%	Consumer Services	8.03%
Cash and Equivalents	3.47%	Cash and Cash Equivalent	3.47%
Canadian Equity	1.12%	Financial Services	2.62%
		Real Estate	2.16%
Geographic allocation	(%)		
United States	60.05%		
Japan	13.66%		
United Kingdom	5.85%		
Germany	5.62%		
Canada	3.94%		
France	3.37%		
Switzerland	3.30%		
Singapore	1.48%		
Other	1.38%		
Brazil	1.35%		

AS AT OCTOBER 31, 2019

## TOP HOLDINGS

	Sector	(%)
1. SeaSpine Holdings Corp	Diversified Healthcare	6.34%
2. Bristol-Myers Squibb Co	Drugs	5.66%
3. Intercept Pharmaceuticals Inc	Drugs	5.52%
4. Biogen Idec Inc	Drugs	5.46%
5. Astellas Pharma Inc	Drugs	5.41%
6. Takeda Pharmaceutical Co Ltd	Drugs	5.07%
7. Alexion Pharmaceuticals Inc	Drugs	5.01%
8. CVS Health Corp	Retail	4.85%
9. GlaxoSmithKline PLC	Drugs	4.19%
10. Fresenius Medical Care AG & Co KGaA	Healthcare Services	3.70%
11. Sanofi SA	Drugs	3.37%
12. Roche Holding AG - Participation	Diversified Healthcare	3.30%
13. Ionis Pharmaceuticals Inc	Drugs	3.30%
14. Sugi Holdings Co Ltd	Retail	3.18%
15. Merit Medical Systems Inc	Drugs	2.78%

## MANAGEMENT TEAM



Altrinsic Global Advisors follows a fundamental value approach to seek out high-quality undervalued companies worldwide. Altrinsic was founded by John Hock and associates and a sub-advisor to CI Investments Inc., a subsidiary of CI Financial Corp. CI Financial Corp. holds a minority interest in Altrinsic Global Advisors.



Andrew Waight

Over 35,000 financial advisors have chosen CI Investments as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. [Learn more at ci.com.](http://ci.com)

<sup>1</sup> Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. The indicated rates of return are the historical annual compounded total returns (net of fees and expenses payable by the fund) including changes in security value and reinvestment of all dividends/distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. Mutual funds are not guaranteed, their values change frequently, and past performance may not be repeated.

<sup>2</sup> Portfolio allocations will fluctuate over the life of the mutual fund as the portfolio holdings and market value of each security changes. The portfolio manager(s) may change the portfolio allocations in some or all of the sectors.

<sup>3</sup> The risk level of a fund has been determined in accordance with a standardized risk classification methodology in National Instrument 81-102, that is based on the fund's historical volatility as measured by the 10-year standard deviation of the fund's returns. Where a fund has offered securities to the public for less than 10 years, the standardized methodology requires that the standard deviation of a reference mutual fund or index that reasonably approximates the fund's standard deviation be used to determine the fund's risk rating. Please note that historical performance may not be indicative of future returns and a fund's historical volatility may not be indicative of future volatility.

<sup>4</sup> Please refer to the fund's simplified prospectus for distribution information.

The contents are not to be used or construed as investment advice or as an endorsement or recommendation of any entity of security discussed.

© CI Investments and the CI Investments design are registered trademarks of CI Investments Inc. © CI Investments Inc. 2019. All rights reserved. 2019. "Trusted Partner in Wealth™" is a trademark of CI Investments Inc.

Published October 2019